Trump Sets 100% Tariff on Generic Drugs With Two-Year Delay - Bloomberg.com

What the report says

Bloomberg reported that President Donald Trump said generic drugmakers will have a two-year window to shift manufacturing to the United States before facing a 100% import duty beginning in August 2028. The report, by Amber Tong and Laura Curtis and updated July 22, 2026, said Trump announced the plan in a social media post as part of an effort to bring production of generic medicines back onshore.

According to Bloomberg, the tariff threat would apply to companies that do not build U.S.-based plants. Trump also said the levy would increase to 200% in August 2029 for manufacturers that remain outside the country. The article described the policy as a potential risk to the supply of lower-cost medicines used by millions of Americans.

The development matters because generic drugs make up a large share of prescriptions in the U.S. and are central to keeping treatment costs lower than brand-name medicines. Bloomberg’s report indicates the administration is using trade penalties to push pharmaceutical supply chains toward domestic production, a goal often framed around national security and resilience.

The available Bloomberg text does not include details on which countries or companies would be most affected, whether exemptions are planned, or how the administration would define sufficient U.S. production. Those implementation questions would be important for drugmakers, pharmacies, insurers and patients as they assess whether the proposed tariffs could raise costs or disrupt supplies.